Interleukin-19 impairment in active Crohn's disease patients

dc.contributor.authorCantó, Elisabet
dc.contributor.authorGarcia Planella, Esther
dc.contributor.authorZamora-Atenza, Carlos
dc.contributor.authorNieto, Juan Camilo
dc.contributor.authorGordillo, Jordi
dc.contributor.authorOrtiz, Ma. Àngels
dc.contributor.authorMetón Teijeiro, Isidoro
dc.contributor.authorSerrano, Elena
dc.contributor.authorVegas Lozano, Esteban
dc.contributor.authorGarcía Bosch, Orlando
dc.contributor.authorJuárez Rubio, Cándido
dc.contributor.authorVidal i Alcorisa, Sílvia
dc.date.accessioned2014-07-16T09:02:16Z
dc.date.available2014-07-16T09:02:16Z
dc.date.issued2014-04-09
dc.date.updated2014-07-16T09:02:18Z
dc.description.abstractThe exact function of interleukin-19 (IL-19) on immune response is poorly understood. In mice, IL-19 up-regulates TNFalpha and IL-6 expression and its deficiency increases susceptibility to DSS-induced colitis. In humans, IL-19 favors a Th2 response and is elevated in several diseases. We here investigate the expression and effects of IL-19 on cells from active Crohn"s disease (CD) patient. Twenty-three active CD patients and 20 healthy controls (HC) were included. mRNA and protein IL-19 levels were analyzed in monocytes. IL-19 effects were determined in vitro on the T cell phenotype and in the production of cytokines by immune cells. We observed that unstimulated and TLR-activated monocytes expressed significantly lower IL-19 mRNA in active CD patients than in HC (logFC =21.97 unstimulated; 21.88 with Pam3CSK4; and 21.91 with FSL-1; p<0.001). These results were confirmed at protein level. Exogenous IL-19 had an anti-inflammatory effect on HC but not on CD patients. IL-19 decreased TNFalpha production in PBMC (850.7675.29 pg/ml vs 2626.06350 pg/ml; p<0.01) and increased CTLA4 expression (22.0461.55% vs 13.9862.05%; p<0.05) and IL-4 production (32.568.9 pg/ml vs 13.562.9 pg/ml; p<0.05) in T cells from HC. IL-10 regulated IL-19 production in both active CD patients and HC. We observed that three of the miRNAs that can modulate IL-19 mRNA expression, were up-regulated in monocytes from active CD patients. These results suggested that IL-19 had an anti-inflammatory role in this study. Defects in IL-19 expression and the lack of response to this cytokine could contribute to inflammatory mechanisms in active CD patients.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec641225
dc.identifier.issn1932-6203
dc.identifier.pmid24718601
dc.identifier.pmid33182538
dc.identifier.urihttps://hdl.handle.net/2445/55853
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://doi.org/10.1371/journal.pone.0093910
dc.relation.ispartofPLoS One, 2014, vol. 9, num. 4, p. e93910
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0093910
dc.rightscc-by (c) Cantó, Elisabet et al., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationCèl·lules T
dc.subject.classificationCitometria de fluxe
dc.subject.classificationCitoquines
dc.subject.classificationLeucòcits
dc.subject.classificationMalaltia de Crohn
dc.subject.classificationMicro RNAs
dc.subject.classificationResposta immunitària
dc.subject.classificationRNA
dc.subject.otherT cells
dc.subject.otherFlow cytometry
dc.subject.otherCytokines
dc.subject.otherLeucocytes
dc.subject.otherCrohn's disease
dc.subject.otherMicroRNAs
dc.subject.otherImmune response
dc.subject.otherRNA
dc.titleInterleukin-19 impairment in active Crohn's disease patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
641225.pdf
Mida:
706.66 KB
Format:
Adobe Portable Document Format